Bupropion Hydrochloride Tablet, Extended Release
Product Images NDC 70436-010

NDC 70436-010-04 R only, this medication is once-daily buPROPion HCI extended-release tablets, which should not be used in combination with ZYBANS or any other medicines containing bupropion hydrochloride. Each tablet contains 150mg of Bupropion hydrochloride, USP. The usual dosage is one tablet daily, as directed by the physician. This medication comes with a medication guide that must be provided to each patient. ZYBAN® is a registered trademark of GlaxcSmitlne. This medicine is dispensed by Slate Run Pharmaceutical, LLC, Columbus, Ohio 43215.*

This is a medication guide for NOC 70436-01002 Reonly, a once-daily extended-release tablet containing Bupropion HCI (XL) USP 160. It is warned not to use in combination with 2YBANS or other medicines containing bupropion hydrochloride. Each tablet contains 160mg of Bupropion hydrochloride. The medication guide should be dispensed separately to each patient. The recommended dosages and storage instructions are listed on the label. The text also mentions that GlaxoSmitiKline is a registered trademark. There is an area for lot serialization data on the coating-free part, but the information is not printed.*

Once-daily bupropion HCI extended-release tablets, USP 150mg are enclosed in Slate Run container with 90 tablets. The medication guide is provided separately to each patient with a warning not to use in combination with Zyban or any other medicines that contain Bupropion hydrochloride. The usual dosage should be taken as prescribed by the physician. It is recommended to store it in a controlled room temperature according to USP with appropriate conditions. The product should be kept out of the reach of children. The registered trademark of Zyban is owned by GlaxoSmithKline. The provided text also contains some manufacturing information like NDC, production site, batch no., and manufacturing date.*

This is a description of a medication called buPROPion HCI in extended-release tablet form with a dosage of 300mg per tablet. The medication is prescribed by a physician and there is a separate medication guide per patient that should be provided by the pharmacist dispensing the drug. The tablets are intended to be taken once daily, either as directed by the physician or as stated on the provided packaging. The medication should be stored at room temperature not exceeding 25°C and kept out of reach of children. The text also includes information regarding the manufacturer, distributor, lot number, and registration details.*

This is a warning label for extended-release tablets containing Bupropion Hydrochloride. The medication is dispensed at room temperature and should be kept away from children. It should not be used in combination with ZYBAN or any other medication containing bupropion hydrochloride. The pharmacist is supposed to dispense the medication guide which includes the dosage schedule. There is also a section on the label that is for serialization data.*

This is a warning about the use of NoC 70436-011-06, which are extended-release tablets that contain 300mg of bupropion hydrochloride. Those who take this medication should not use it with ZYBAN or any other similar drugs. Pharmacies should provide each patient with a separate medication guide. The tablets must be kept in a cool, dry place and away from children. The manufacturer is Slate Run Pharmaceuticals, LLC, operating out of Columbus, Ohio.*